Strides Pharma Science Q4FY26 net profit rose 51 percent to 129.2 crore on 11.2 percent higher revenue, board proposed 5 rupee final dividend, net debt to EBITDA improved to 1.55x
Strides Pharma Science Q4FY26 net profit rose 51 percent to 129.2 crore on 11.2 percent higher revenue, board proposed 5 rupee final dividend, net debt to EBITDA improved to 1.55x